Allergan Seeks To Extend Botox Use To Overactive Bladder
This article was originally published in The Pink Sheet Daily
Executive Summary
During an R&D day March 28, Allergan highlighted its growth strategy for Botox, which includes expansion into new indications like overactive bladder; the company submitted an sBLA for the indication.
You may also be interested in...
Astellas Expands Its Presence In Urology With Myrbetriq Approval
Astellas is tasked with introducing a new product into the already crowded overactive bladder market now that it has gained approval for the beta-3 antagonist mirabegron in the U.S.
A Headache For Map: Levadex Gets “Complete Response” Letter From FDA
The agency raised issues related to the chemistry, manufacturing and controls section of the dihydroergotamine NDA, as well as concerns stemming from inspection of a third-party manufacturing facility, the company says.
Allergan And MAP Team Up On Inhalable Migraine Treatment
Deal with Allergan focuses on detailing to neurologists and pain specialists, leaving MAP free to do other co-promotion deals.